Pharmaceuticals France

France Parkinson's Disease Treatment Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

France Parkinson's Disease Treatment Market Industry Trends and Forecast to 2034: Segmented by (Treatment, Stage, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

France · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $187.8 Mn Placeholder estimate
Estimate 2025 $197.0 Mn 2.7% of the global market
Projected 2034 $303.0 Mn 53.8% Adds $106.0 Mn over 9 forecast years
CAGR 2025–2034 4.9% Faster than 22% of 186 Pharmaceuticals markets here
Key players 5
  • France is 2.7% of the global market.
  • In Europe, the largest is Germany at $249.5 Mn.
  • Fastest growing: Italy at 5.9% a year.
  • France ranks 2nd of 6 by size in Europe.

Market size projection

France

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$106.0 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Parkinson's Disease Treatment Market market size by year, France
YearMarket sizeChange that yearSince 2025
2024 (estimate) $187.8 Mn — —
2025 (base) $197.0 Mn +$9.2 Mn —
2026 (forecast) $206.6 Mn +$9.7 Mn +4.9%
2027 (forecast) $216.7 Mn +$10.1 Mn +10%
2028 (forecast) $227.4 Mn +$10.6 Mn +15.4%
2029 (forecast) $238.5 Mn +$11.1 Mn +21.1%
2030 (forecast) $250.2 Mn +$11.7 Mn +27%
2031 (forecast) $262.5 Mn +$12.3 Mn +33.2%
2032 (forecast) $275.3 Mn +$12.9 Mn +39.8%
2033 (forecast) $288.8 Mn +$13.5 Mn +46.6%
2034 (forecast) $303.0 Mn +$14.2 Mn +53.8%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

France Parkinson's Disease Treatment Market Analysis at a glance
Market size, 2025$197.0 Mn placeholder estimate
Forecast, 2034$303.0 Mn placeholder estimate
Growth (CAGR), 2025–20344.9% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTreatment, stage and end user (see all)
Key playersAbbVie Inc., Supernus Pharmaceuticals, Amneal Pharmaceuticals, Inc, Medtronic, UCB (see all)
Regulator in FranceANSMSource: ANSM, French medicines agency. Checked 14 Nov 2026.
Active clinical trials98 in FranceSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in France. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The France Parkinson's Disease Treatment Market Analysis Executive Summary

Parkinson's disease treatments ease tremor, stiffness and slowness with medicines, pumps and brain stimulation.

Key segments of the parkinson's Disease Treatment market include treatment (Levodopa-Based Drugs, Dopamine Agonists and MAO-B Inhibitors) and stage (Early and Advanced).

Bar chart: France Parkinson's Disease Treatment market size, 2024–2034, placeholder estimates. $187.8 Mn in 2024, $197.0 Mn in 2025 and $303.0 Mn in 2034, 4.9% CAGR.
France Parkinson's Disease Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

France Parkinson's Disease Treatment Market Dynamics

Market Growth Drivers

An ageing population, more people living with brain and nerve diseases, better diagnosis and the first disease-modifying treatments are driving the parkinson's Disease Treatment market.

Opportunity

Biomarker-guided treatment, earlier diagnosis and new device-based therapies give the parkinson's Disease Treatment market strong room to grow.

Market Restraints

Hard-to-reach brain targets, high failure rates in trials, side effects and high prices for new therapies hold back the parkinson's Disease Treatment market.

Competitive Landscape for Parkinson's Disease Treatment Market in France

The parkinson's Disease Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Parkinson's Disease Treatment Market in France

Parkinson's Disease Treatment in France: rules, payment and research

Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by ANSM, the French medicines agency.⁠[1] National health insurance (Assurance Maladie) pays back part of most care costs, and the HAS, the French National Authority for Health, advises on what it should cover.⁠[2] ClinicalTrials.gov lists 98 studies on Parkinson's Disease Treatment that are recruiting, active or about to start in France.⁠[3]

[1] ANSM, French medicines agency. Checked 14 Nov 2026.

[2] Assurance Maladie (ameli.fr). Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in France. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for parkinson's Disease Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in France.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Parkinson's Disease Treatment right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Parkinson's Disease Treatment in context

France compared

  • Health spending per person: 5,327 US$ per person (2024). World: 1,317 US$ per person (2023). 8th highest of the 13 countries we cover in Europe.[1]
  • Doctors: 3.28 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 12th highest of the 13 countries we cover in Europe.[2]
  • People aged 65 and over: 22.5% of people (2025). World: 10.4% of people (2025). 3rd highest of the 13 countries we cover in Europe.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 22 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 22 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 22 Nov 2026.

Free data on this topic

Inside France

Quick answers

Frequently asked questions

How big is the Parkinson's Disease Treatment market in France?
Placeholder estimate: about $197.0 Mn in 2025, rising to about $303.0 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Parkinson's Disease Treatment market in France growing?
Placeholder estimate: about 4.9% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Parkinson's Disease Treatment market report cover?
The report splits the market by treatment (Levodopa-Based Drugs, Dopamine Agonists, MAO-B Inhibitors, Continuous Infusion and more), stage (Early, Advanced) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Parkinson's Disease Treatment market?
Key players include AbbVie Inc., Supernus Pharmaceuticals, Amneal Pharmaceuticals, Inc, Medtronic and UCB.
What is driving the Parkinson's Disease Treatment market?
An ageing population, more people living with brain and nerve diseases, better diagnosis and the first disease-modifying treatments are driving the parkinson's Disease Treatment market.
Who regulates Parkinson's Disease Treatment in France?
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by ANSM, the French medicines agency. Source: ANSM, French medicines agency. Checked 14 Nov 2026.
How is healthcare paid for in France?
National health insurance (Assurance Maladie) pays back part of most care costs, and the HAS, the French National Authority for Health, advises on what it should cover. Source: Assurance Maladie (ameli.fr). Checked 14 Nov 2026.
How many clinical trials on Parkinson's Disease Treatment are running in France?
98 studies are recruiting, active or about to start in France, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in France. Retrieved 12 Nov 2026.
How much research is published on Parkinson's Disease Treatment?
PubMed lists 198 papers on Parkinson's Disease Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in France

See all

Related on brain and nerves

See the topic